Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 14 for:    Octaplex and fresh frozen plasma
Previous Study | Return to List | Next Study

Study of OCTAPLEX and FFP in Patients Under Vit K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

This study has been completed.
Information provided by (Responsible Party):
Octapharma Identifier:
First received: February 5, 2008
Last updated: April 10, 2013
Last verified: April 2013
The purpose of this study is to determine whether Octaplex works at reversing the effects of the anticoagulants when compared to the standard treatment of receiving fresh frozen plasma (FFP).

Condition Intervention Phase
Reversal of Anticoagulant Treatment
Drug: prothrombin complex concentrate
Biological: Fresh Frozen Plasma
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Efficacy and Safety Study of OCTAPLEX and Fresh Frozen Plasma (FFP) in Patients Under Vitamin k Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures

Resource links provided by NLM:

Further study details as provided by Octapharma:

Primary Outcome Measures:
  • There will be two primary end points in this study. The first primary efficacy endpoint is the correction of INR to < 1.5. [ Time Frame: 15 minutes after the end of first infusion of OCTAPLEX or FFP ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • number of intra-operative red blood cell units (RBC) transfused [ Time Frame: intra-operative ] [ Designated as safety issue: Yes ]

Enrollment: 200
Study Start Date: April 2008
Study Completion Date: August 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: prothrombin complex concentrate
The OCTAPLEX dose will depend on the weight and baseline INR of the patient and will be calculated by the responsible treating investigator based on the dosing formula and the pre-defined INR to a value of <1.5.
Active Comparator: 2 Biological: Fresh Frozen Plasma
The dose of FFP will depend on the weight and baseline INR of the patient. FFP will be given as a continuous intravenous infusion. The dosage should be 10 mL/kg for a patient that has an initial INR of <3 and 15 mL/kg for a patient that has an initial INR of >3. This will be given over 90 minutes or as fast as clinically indicated or tolerated by the patient at the discretion of the investigator (each unit of FFP contains roughly 200 mL).
Other Name: FFP

Detailed Description:

The primary objective of the study is to demonstrate the efficacy of OCTAPLEX as a reversal agent in patients under vitamin K antagonist therapy with the need for urgent surgery or invasive procedures is not clinically inferior to that of FFP.

The secondary objective of the study is to investigate the safety and tolerability of OCTAPLEX compared to FFP in patients under vitamin K antagonist therapy with the need for urgent surgery or invasive procedures


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients at least 18 years of age.
  • Patients receiving oral anticoagulation with coumadin or warfarin derived agents.
  • Patients who have need for urgent surgery or an invasive procedure up to 8 hours after admission or identification of a patient currently hospitalized, where oral or parenteral vitamin K therapy is deemed too slow in its action for reversal of coumadin or warfarin anticoagulant effects.
  • Patients with an international normalized ratio (INR) of 2.0 or above.
  • Patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf.
  • Patients able and willing to comply with the procedures laid out in the study protocol. In the case of unconscious and/or incapacitated patients, the willingness of the patient's legal representative for the patient to undergo the procedures laid out in the study protocol.

Exclusion Criteria:

  • Patients with a life expectancy of less than 48 hours (e.g. Patients with a GCS [Glasgow Coma Scale] equal to 3 or a head AIS [abbreviated injury score] of 6, patients requiring continuous inotropic or pressor support, patients status post cardiac arrest) (Appendix 7).
  • Patients with a history within the last 6 months, of disseminated intravascular coagulation (DIC), or hyperfibrinolysis.
  • Patients with a known congenital coagulation disorder.
  • Patients with known antiphospholipid antibody syndrome or have known lupus anticoagulant antibodies.
  • Patients with present or past specific factor inhibitor activity.
  • Patients with thrombocytopenia of <80,000 or history of heparin induced thrombocytopenia (HIT).
  • Patients having received heparin of any type or any non coumadin or warfarin anticoagulant immediately prior and/or intended to be given within the first 1 hr post-infusion.
  • Patients who have received vitamin K more than 3 hours prior to the infusion of study drug.
  • Patients with a history of hypersensitivity to plasma-derived products.
  • Pregnant or nursing women.
  • Patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion.
  • Patients previously enrolled in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00618098

United States, Pennsylvania
Contact Octapharma for Facility details
Philadelphia, Pennsylvania, United States, 19141
Sponsors and Collaborators
Study Director: Wolfgang Frenzel, MD International Medical Director
  More Information

Responsible Party: Octapharma Identifier: NCT00618098     History of Changes
Other Study ID Numbers: LEX-205 
Study First Received: February 5, 2008
Last Updated: April 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Octapharma:
anticoagulant reversal
urgent surgery
invasive procedures
vitamin K
prothrombin complex concentrate

Additional relevant MeSH terms:
Vitamin K
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs processed this record on September 28, 2016